|
1
|
Foucher ED, Ghigo C, Chouaib S, Galon J,
Iovanna J and Olive D: Pancreatic ductal adenocarcinoma: A strong
imbalance of good and bad immunological cops in the tumor
microenvironment. Front Immunol. 9:10442018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zheng L, Xue J, Jaffee EM and Habtezion A:
Role of immune cells and immune-based therapies in pancreatitis and
pancreatic ductal adenocarcinoma. Gastroenterology. 144:1230–1240.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shi C, Merchant N, Newsome G, Goldenberg
DM and Gold DV: Differentiation of pancreatic ductal adenocarcinoma
from chronic pancreatitis by PAM4 immunohistochemistry. Archives
Pathol Lab Med. 138:220–228. 2014. View Article : Google Scholar
|
|
4
|
Hernandez JM, Cowgill SM, Al-Saadi S,
Collins A, Ross SB, Cooper J, Villadolid D, Zervos E and Rosemurgy
A: CA 19-9 velocity predicts disease-free survival and overall
survival after pancreatectomy of curative intent. J Gastrointest
Surg. 13:349–353. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Winter JM, Yeo CJ and Brody JR:
Diagnostic, prognostic, and predictive biomarkers in pancreatic
cancer. J Surg Oncol. 107:15–22. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Marengo E and Robotti E: Biomarkers for
pancreatic cancer: Recent achievements in proteomics and genomics
through classical and multivariate statistical methods. World J
Gastroenterol. 20:13325–13342. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Roxburgh CS and McMillan DC: Role of
systemic inflammatory response in predicting survival in patients
with primary operable cancer. Future Oncol. 6:149–163. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Koh YW, Kang HJ, Park C, Yoon DH, Kim S,
Suh C, Go H, Kim JE, Kim CW and Huh J: The ratio of the absolute
lymphocyte count to the absolute monocyte count is associated with
prognosis in hodgkin's lymphoma: Correlation with tumor-associated
macrophages. Oncologist. 17:871–880. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kaynar M, Yildirim ME, Badem H, Cavis M,
Tekinarslan E, Istanbulluoglu MO, Karatas OF and Cimentepe E:
Bladder cancer invasion predictability based on preoperative
neutrophil-lymphocyte ratio. Tumour Biol. 35:6601–6605. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tanoglu A and Karagoz E: Neutrophil and
platelet-to-lymphocyte ratio: New predictors of dropout and
recurrence after liver transplantation for hepatocellular cancer?
Transplant Int. 27:e80–e81. 2014. View Article : Google Scholar
|
|
12
|
McMillan DC: Systemic inflammation,
nutritional status and survival in patients with cancer. Curr Opin
Clin Nutr Metab Care. 12:223–226. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Martin HL, Ohara K, Kiberu A, Van Hagen T,
Davidson A and Khattak MA: Prognostic value of systemic
inflammation-based markers in advanced pancreatic cancer. Intern
Med J. 44:676–682. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Aliustaoglu M, Bilici A, Seker M, Dane F,
Gocun M, Konya V, Ustaalioglu BB and Gumus M: The association of
pre-treatment peripheral blood markers with survival in patients
with pancreatic cancer. Hepatogastroenterology. 57:640–645.
2010.PubMed/NCBI
|
|
15
|
Sierzega M, Lenart M, Rutkowska M, Surman
M, Mytar B, Matyja A, Siedlar M and Kulig J: Preoperative
neutrophil-lymphocyte and lymphocyte-monocyte ratios reflect immune
cell population rearrangement in resectable pancreatic cancer. Ann
Surg Oncol. 24:808–815. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Garrett SC, Varney KM, Weber DJ and
Bresnick AR: S100A4, a mediator of metastasis. J Biol Chem.
281:677–680. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liang J, Piao Y, Holmes L, Fuller GN,
Henry V, Tiao N and de Groot JF: Neutrophils promote the malignant
glioma phenotype through S100A4. Clin Cancer Res. 20:187–198. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hansen MT, Forst B, Cremers N, Quagliata
L, Ambartsumian N, Grum-Schwensen B, Klingelhofer J, Abdul-Al A,
Herrmann P, Osterland M, et al: A link between inflammation and
metastasis: Serum amyloid A1 and A3 induce metastasis, and are
targets of metastasis-inducing S100A4. Oncogene. 34:424–435. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dahlmann M, Kobelt D, Walther W, Mudduluru
G and Stein U: S100A4 in cancer metastasis: Wnt signaling-driven
interventions for metastasis restriction. Cancers (Basel).
8:E592016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Grum-Schwensen B, Klingelhofer J,
Grigorian M, Almholt K, Nielsen BS, Lukanidin E and Ambartsumian N:
Lung metastasis fails in MMTV-PyMT oncomice lacking S100A4 due to a
T-cell deficiency in primary tumors. Cancer Res. 70:936–947. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yao R, Davidson DD, Lopez-Beltran A,
MacLennan GT, Montironi R and Cheng L: The S100 proteins for
screening and prognostic grading of bladder cancer. Histol
Histopathol. 22:1025–1032. 2007.PubMed/NCBI
|
|
22
|
Ai KX, Lu LY, Huang XY, Chen W and Zhang
HZ: Prognostic significance of S100A4 and vascular endothelial
growth factor expression in pancreatic cancer. World J
Gastroenterol. 14:1931–1935. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kamarajah SK, Burns WR, Frankel TL, Cho CS
and Nathan H: Validation of the american joint commission on cancer
(AJCC) 8th edition staging system for patients with pancreatic
adenocarcinoma: A surveillance, epidemiology and end results (SEER)
analysis. Ann Surg Oncol. 24:2023–2030. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tian X, Zhou D, Chen L, Tian Y, Zhong B,
Cao Y, Dong Q, Zhou M, Yan J, Wang Y, et al: Polo-like kinase 4
mediates epithelial-mesenchymal transition in neuroblastoma via
PI3K/Akt signaling pathway. Cell Death Dis. 9:542018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Garcea G, Ladwa N, Neal CP, Metcalfe MS,
Dennison AR and Berry DP: Preoperative neutrophil-to-lymphocyte
ratio (NLR) is associated with reduced disease-free survival
following curative resection of pancreatic adenocarcinoma. World J
Surg. 35:868–872. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Smith RA, Bosonnet L, Raraty M, Sutton R,
Neoptolemos JP, Campbell F and Ghaneh P: Preoperative
platelet-lymphocyte ratio is an independent significant prognostic
marker in resected pancreatic ductal adenocarcinoma. Am J Surg.
197:466–472. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kakkat S, Rajan R, Sindhu RS, Natesh B and
Raviram S: Comparison of platelet-lymphocyte ratio and CA 19-9 in
differentiating benign from malignant head masses in patients with
chronic pancreatitis. Indian J Gastroenterol. 36:263–267. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Asari S, Matsumoto I, Toyama H, Shinzeki
M, Goto T, Ishida J, Ajiki T, Fukumoto T and Ku Y: Preoperative
independent prognostic factors in patients with borderline
resectable pancreatic ductal adenocarcinoma following curative
resection: The neutrophil-lymphocyte and platelet-lymphocyte
ratios. Surg Today. 46:583–592. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jia W, Gao XJ, Zhang ZD, Yang ZX and Zhang
G: S100A4 silencing suppresses proliferation, angiogenesis and
invasion of thyroid cancer cells through downregulation of MMP-9
and VEGF. Eur Rev Med Pharmacol Sci. 17:1495–1508. 2013.PubMed/NCBI
|
|
30
|
Tsukamoto N, Egawa S, Akada M, Abe K,
Saiki Y, Kaneko N, Yokoyama S, Shima K, Yamamura A, Motoi F, et al:
The expression of S100A4 in human pancreatic cancer is associated
with invasion. Pancreas. 42:1027–1033. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mahon PC, Baril P, Bhakta V, Chelala C,
Caulee K, Harada T and Lemoine NR: S100A4 contributes to the
suppression of BNIP3 expression, chemoresistance, and inhibition of
apoptosis in pancreatic cancer. Cancer Res. 67:6786–6795. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lee SH, Kim H, Hwang JH, Shin E, Lee HS,
Hwang DW, Cho JY, Yoon YS, Han HS and Cha BH: CD24 and S100A4
expression in resectable pancreatic cancers with earlier disease
recurrence and poor survival. Pancreas. 43:380–388. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Arumugam T, Ramachandran V, Gomez SB,
Schmidt AM and Logsdon CD: S100P-derived RAGE antagonistic peptide
reduces tumor growth and metastasis. Clin Cancer Res. 18:4356–4364.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Langley RR and Fidler IJ: The seed and
soil hypothesis revisited-the role of tumor-stroma interactions in
metastasis to different organs. Int J Cancer. 128:2527–2535. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Knudsen ES, Vail P, Balaji U, Ngo H,
Botros IW, Makarov V, Riaz N, Balachandran V, Leach S, Thompson DM,
et al: Stratification of pancreatic ductal adenocarcinoma:
Combinatorial genetic, stromal, and immunological markers. Clin
Cancer Res. 23:4429–4440. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Raphael BJ, Hruban RH, Aguirre AJ, Moffitt
RA, Yeh JJ, Stewart C, Robertson AG, Cherniack AD, Gupta M, Getz G,
et al: Integrated genomic characterization of pancreatic ductal
adenocarcinoma. Cancer Cell. 14:185–203. 2017. View Article : Google Scholar
|
